Oruka Therapeutics Inc (ORKA)

$12.58 +0.39 (3.20%)
Market Cap 471.01M
Revenue (ttm) 0.00
Net Income (ttm) -83.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 138,300
Avg Vol 243,860
Day's Range N/A - N/A
Shares Out 37.44M
Stochastic %K 87%
Beta -0.38
Analysts Strong Sell
Price Target $39.50

Latest News on ORKA

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

May 21, 2025, 7:00 AM EDT - 18 days ago

Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

May 20, 2025, 4:01 PM EDT - 19 days ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 4:15 PM EDT - 25 days ago

Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Apr 29, 2025, 7:00 AM EDT - 5 weeks ago

Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Mar 7, 2025, 8:30 AM EST - 3 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Mar 6, 2025, 4:09 PM EST - 3 months ago

Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple March Investor Conferences

Feb 19, 2025, 7:00 AM EST - 3 months ago

Oruka Therapeutics to Present at Multiple March Investor Conferences

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Dec 19, 2024, 7:00 AM EST - 6 months ago

Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Dec 18, 2024, 7:00 AM EST - 6 months ago

Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 4:25 PM EST - 7 months ago

Oruka Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oruka Therapeutics to Present at Multiple November Investor Conferences

Nov 4, 2024, 7:00 AM EST - 7 months ago

Oruka Therapeutics to Present at Multiple November Investor Conferences

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Sep 25, 2024, 7:08 AM EDT - 9 months ago

Oruka Therapeutics Announces Preclinical Data for ORKA-001 at the European Academy of Dermatology and Venereology Congress

Oruka Therapeutics Announces $200 Million Private Placement

Sep 12, 2024, 7:05 AM EDT - 9 months ago

Oruka Therapeutics Announces $200 Million Private Placement

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

Aug 29, 2024, 4:50 PM EDT - 10 months ago

ARCA biopharma Announces Completion of Merger with Oruka Therapeutics and Implementation of Reverse Stock Split

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

Aug 26, 2024, 7:30 PM EDT - 10 months ago

ARCA biopharma Provides Update Regarding Special Dividend Amount in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

Aug 23, 2024, 4:30 PM EDT - 10 months ago

ARCA biopharma Announces 1-for-12 Reverse Stock Split in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

Aug 16, 2024, 4:15 PM EDT - 10 months ago

ARCA biopharma Declares Special Dividend in Connection with the Proposed Merger with Oruka Therapeutics

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 4:15 PM EDT - 11 months ago

ARCA biopharma Announces Second Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

May 10, 2024, 6:34 PM EDT - 1 year ago

ARCA BIOPHARMA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

Apr 25, 2024, 4:15 PM EDT - 1 year ago

ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Apr 5, 2024, 1:27 PM EDT - 1 year ago

ARCA BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ARCA biopharma, Inc. - ABIO

Arca Biopharma stock ($ABIO) soars on merger news

Apr 3, 2024, 11:38 AM EDT - 1 year ago

Arca Biopharma stock ($ABIO) soars on merger news

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

Apr 3, 2024, 7:30 AM EDT - 1 year ago

ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

ARCA biopharma Announces 2023 Financial Results

Feb 1, 2024, 4:35 PM EST - 1 year ago

ARCA biopharma Announces 2023 Financial Results

ARCA biopharma Announces Third Quarter 2023 Financial Results

Oct 18, 2023, 4:25 PM EDT - 1 year ago

ARCA biopharma Announces Third Quarter 2023 Financial Results

ARCA biopharma Announces Second Quarter 2023 Financial Results

Jul 21, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces Second Quarter 2023 Financial Results

ARCA biopharma Announces First Quarter 2023 Financial Results

Apr 24, 2023, 4:25 PM EDT - 2 years ago

ARCA biopharma Announces First Quarter 2023 Financial Results

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

Feb 24, 2023, 4:20 PM EST - 2 years ago

ARCA biopharma Announces 2022 Financial Results and Provides Corporate Update

James Flynn Joins ARCA biopharma Board of Directors

Dec 19, 2022, 4:05 PM EST - 2 years ago

James Flynn Joins ARCA biopharma Board of Directors

ARCA biopharma Announces Third Quarter 2022 Financial Results

Oct 28, 2022, 4:15 PM EDT - 2 years ago

ARCA biopharma Announces Third Quarter 2022 Financial Results

ARCA biopharma Announces Second Quarter 2022 Financial Results

Aug 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Second Quarter 2022 Financial Results

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

Jun 21, 2022, 4:05 PM EDT - 3 years ago

Jacob Ma-Weaver Joins ARCA biopharma Board of Directors

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

May 5, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Retains Ladenburg Thalmann to Support Strategic Options Review

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

May 3, 2022, 11:50 AM EDT - 3 years ago

ARCA biopharma: Activist's Pressure Could Make This Into A Liquidation Play

ARCA biopharma Announces First Quarter 2022 Financial Results

May 2, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces First Quarter 2022 Financial Results

ARCA biopharma Establishes Special Committee of the Board of Directors

Apr 18, 2022, 4:30 PM EDT - 3 years ago

ARCA biopharma Establishes Special Committee of the Board of Directors

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

Apr 1, 2022, 7:21 AM EDT - 3 years ago

ARCA biopharma's Tissue Factor Inhibitor Disappoints In Mid-Stage COVID-19 Study

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Mar 31, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Mar 14, 2022, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces 2021 Financial Results and Provides Corporate Update

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

Jan 4, 2022, 8:30 AM EST - 3 years ago

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

Dec 2, 2021, 8:30 AM EST - 3 years ago

ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

Nov 9, 2021, 4:15 PM EST - 3 years ago

ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Nov 2, 2021, 4:15 PM EDT - 3 years ago

ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged

Oct 29, 2021, 6:26 AM EDT - 3 years ago

ARCA Biopharma Stock Gains As Safety Committee Recommends COVID-19 Trial To Continue Unchanged

ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data

Oct 28, 2021, 4:30 PM EDT - 3 years ago

ASPEN-COVID-19 Data and Safety Monitoring Committee Recommends Continuing Phase 2b Clinical Trial to Completion Based on Interim Analysis of Efficacy and Safety Data

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

Sep 16, 2021, 8:30 AM EDT - 4 years ago

ARCA biopharma Announces Enrollment of First International Patient in Phase 2b Clinical Trial Evaluating rNAPc2 as a Potential Treatment for COVID-19

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th

Aug 16, 2021, 8:05 AM EDT - 4 years ago

ARCA biopharma to Present at the Q3 Virtual Investor Summit on August 18th